Soleno Therapeutics (SLNO) Soars 30% on $2.5B+ Neurocrine Acquisition Talks

Key Highlights

Table of Contents

Shares of Soleno Therapeutics (SLNO) jumped more than 30% during premarket hours Monday following acquisition reports
Neurocrine Biosciences (NBIX) has entered late-stage negotiations to purchase Soleno for upwards of $2.5 billion
The proposed transaction could price SLNO shares in the low-to-mid $50 range
According to the Financial Times, an agreement may be reached as early as Monday, April 6
Neurocrine shares declined 0.4% premarket following the announcement

Soleno Therapeutics has experienced a challenging start to 2026 — sliding approximately 14% since January — but Monday morning brought a dramatic reversal.

Soleno Therapeutics, Inc., SLNO

According to a Financial Times report, Neurocrine Biosciences has entered advanced acquisition discussions with the rare disease-focused biotech company in a transaction valued at over $2.5 billion. News of the potential buyout drove SLNO shares more than 30% higher in premarket activity.

Neurocrine nears $2.5bn-plus deal for biotech behind obesity disorder treatment https://t.co/t7RIhvgwIb

— Financial Times (@FT) April 6, 2026

The proposed acquisition would establish a valuation for Soleno ranging from the low-to-mid $50s per share. Negotiations are progressing swiftly, with the FT indicating that both parties could finalize terms as soon as Monday.

Soleno’s primary commercial product is Vykat XR, a treatment launched in the previous year targeting hyperphagia — a medical condition associated with Prader-Willi syndrome. This condition triggers relentless, excessive hunger that can result in severe health consequences such as gastric rupture, choking hazards, obesity, and heart-related illnesses.

Prader-Willi syndrome represents a rare genetic abnormality, affecting approximately one in 15,000 births. Vykat XR stands as the inaugural commercialized therapy authorized for managing hunger-driven symptoms in patients with this syndrome.

Industry analysts project Vykat XR could achieve peak yearly revenues reaching $2.3 billion — a projection that has evidently attracted significant interest from Neurocrine.

Neurocrine Expands Into Rare Disease Territory

Neurocrine currently maintains a market valuation near $13.21 billion. The company’s existing product lineup features Ingrezza, designed to address involuntary motor movements in Huntington’s disease patients, alongside additional approved therapeutics and developmental candidates.

Acquiring Vykat XR would establish Neurocrine’s presence in the rare disease and orphan medication sector, where companies typically enjoy favorable pricing dynamics and reduced competitive pressures.

Neurocrine’s shares fell 0.4% during premarket trading Monday. Such modest declines are common when acquiring companies announce deals — reflecting investor concerns about premium payments.

Understanding SLNO’s Recent Performance

Despite Monday’s dramatic surge, SLNO had declined roughly 14% in 2026 before this development. The shares had underperformed despite favorable analyst projections regarding Vykat XR’s revenue potential.

According to TipRanks, SLNO maintains a Strong Buy rating based on input from 11 analysts. The consensus price target stands at $101.09, with the most bullish forecast reaching $125.

If completed at the reported valuation of low-to-mid $50s per share, this transaction would fall considerably short of analyst price targets — although it would still deliver a meaningful premium over SLNO’s recent trading levels.

The Financial Times report referenced sources with direct knowledge of the negotiations, emphasizing that discussions are advancing positively and accelerating toward a possible finalized agreement.

✨ Limited Time Offer